HealthCare Global Enterprises board approves ₹425-crore rights issue

Cancer-focused healthcare service provider HealthCare Global Enterprises Ltd on Tuesday (February 17) said its board of directors has approved the issuance of fully paid-up equity shares through a rights issue to eligible shareholders. The total amount to be raised under the issuance will not exceed ₹₹425 crore.

The rights issue will be offered to equity shareholders as on a record date to be determined and notified by the company. The board or the Rights Issue Committee will decide the specific terms, including the issue price, rights entitlement ratio, record date, timing of the rights issue, and terms of payment.

Last year in September, Aceso Company, part of the CVC Network, sold nearly a 6% stake in HealthCare Global Enterprises (HCG) via a block deal on the NSE, raising ₹552 crore at an average price of ₹695 per share.

Also Read: HCG eyes 20% margin in FY26 amid outpatient shift, strong urban growth

Of the 79 lakh shares sold, Nippon India Mutual Fund bought 44 lakh shares worth ₹306 crore, increasing its stake by 3.2% on top of the 2.5% it already held as of June 2025. Other buyers included Plutus Wealth Management (₹50 crore), Axis Mutual Fund (₹66 crore), and Morgan Stanley Asia Singapore (₹61 crore). Motilal Oswal AMC also picked up three lakh shares worth ₹21 crore.

Tata Asset Management (4.1%) and Motilal Oswal AMC (2.8%) are among the other prominent domestic fund holders in HCG. Foreign portfolio investors, meanwhile, collectively own 2.2% of the company.

HealthCare Global Enterprises operates cancer treatment clinics, multispeciality hospitals, and fertility treatment centres.

Shares of Healthcare Global Enterprises Ltd ended at ₹578.60, down by ₹5.80, or 0.99%, on the BSE today, February 17.

Also Read: Insurer–hospital row hurt sentiment, not patient footfall, says InCred’s Aditya Khemka